148 related articles for article (PubMed ID: 36419690)
1. Adding pre-emptive anticholinergics to antipsychotics: Is it justified?
Chatterjee K; Dangi A; Sharma R; Yadav P; Chauhan VS; Prakash J
Ind Psychiatry J; 2022; 31(2):370-373. PubMed ID: 36419690
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotics in the treatment of schizophrenia: an overview.
Tandon R
J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
[TBL] [Abstract][Full Text] [Related]
3. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
4. EPS profiles: the atypical antipsychotics are not all the same.
Weiden PJ
J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
[TBL] [Abstract][Full Text] [Related]
5. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
Ogino S; Miyamoto S; Miyake N; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
[TBL] [Abstract][Full Text] [Related]
6. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.
Weng J; Zhang Y; Li H; Shen Y; Yu W
Gen Psychiatr; 2019; 32(1):e100026. PubMed ID: 31179423
[TBL] [Abstract][Full Text] [Related]
7. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
Desmarais JE; Beauclair L; Margolese HC
J Psychopharmacol; 2012 Sep; 26(9):1167-74. PubMed ID: 22651987
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.
Haddad PM; Das A; Keyhani S; Chaudhry IB
J Psychopharmacol; 2012 May; 26(5 Suppl):15-26. PubMed ID: 22057019
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.
Hong IS; Bishop JR
Ann Pharmacother; 2010; 44(7-8):1171-80. PubMed ID: 20587746
[TBL] [Abstract][Full Text] [Related]
11. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.
Yang SY; Kao Yang YH; Chong MY; Yang YH; Chang WH; Lai CS
Clin Pharmacol Ther; 2007 Apr; 81(4):586-94. PubMed ID: 17235331
[TBL] [Abstract][Full Text] [Related]
12. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.
Peluso MJ; Lewis SW; Barnes TR; Jones PB
Br J Psychiatry; 2012 May; 200(5):387-92. PubMed ID: 22442101
[TBL] [Abstract][Full Text] [Related]
13. The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population.
Kadakia A; Brady BL; Dembek C; Williams GR; Kent JM
J Med Econ; 2022; 25(1):87-98. PubMed ID: 34913797
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
Monteleone P; Cascino G; Monteleone AM; Rocca P; Rossi A; Bertolino A; Aguglia E; Amore M; Collantoni E; Corrivetti G; Cuomo A; Bellomo A; D'Ambrosio E; Dell'Osso L; Frascarelli M; Giordano GM; Giuliani L; Marchesi C; Montemagni C; Oldani L; Pinna F; Pompili M; Roncone R; Rossi R; Siracusano A; Vita A; Zeppegno P; Galderisi S; Maj M;
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110250. PubMed ID: 33484755
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of antipsychotic-induced extrapyramidal side effects in east Indians: cultural practice or biological necessity?
Dhavale HS; Pinto C; Dass J; Nayak A; Kedare J; Kamat M; Dewan M
J Psychiatr Pract; 2004 May; 10(3):200-2. PubMed ID: 15330229
[TBL] [Abstract][Full Text] [Related]
16. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents.
Gjerden P; Slørdal L; Bramness JG
Eur J Clin Pharmacol; 2009 Dec; 65(12):1229-35. PubMed ID: 19644682
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009).
Xiang YT; Kreyenbuhl J; Dickerson FB; Ungvari GS; Wang CY; Si TM; Lee EH; Chiu HF; Lai KY; He YL; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong MK; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
Int J Clin Pharmacol Ther; 2012 Jul; 50(7):500-4. PubMed ID: 22541750
[TBL] [Abstract][Full Text] [Related]
18. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics.
Caradoc-Davies G; Menkes DB; Clarkson HO; Mullen PE
Aust N Z J Psychiatry; 1986 Jun; 20(2):225-32. PubMed ID: 2876700
[TBL] [Abstract][Full Text] [Related]
19. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.
Pierre JM
Drug Saf; 2005; 28(3):191-208. PubMed ID: 15733025
[TBL] [Abstract][Full Text] [Related]
20. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
